



*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

## Pomalidomide

August 6, 2015

### **Non-proprietary name**

Pomalidomide

### **Safety measure**

Precautions should be revised in the package insert.

In the Clinically significant adverse reactions subsection of the Adverse reactions section, the following text should be added (underlined parts are revised):

#### Hepatic function disorder and jaundice:

Hepatic function disorder or jaundice associated with elevated AST (GOT), ALT (GPT),  $\gamma$ -GTP, or bilirubin levels may occur. Patients should be carefully monitored through periodic testing, etc. If any abnormalities are observed, appropriate measures such as dose reduction, drug suspension, or discontinuation of administration should be adopted.